A fresh analysis of the clinical and financial implications of comprehensive coverage in Medicare of GLP-1s for all current FDA indications (type 2 diabetes, obesity, heart disease and metabolic-associated steatohepatitis) offers some hope for long-term cost savings
"Treatment with semaglutide, at low doses, significantly reduces body weight in almost 80% of obese PCOS patients who were unresponsive to a previous lifestyle plan." - Enrico Carmina, MD This highlights how critical it is to stay consistent with treatment to achieve and maintain these results
Vendor documentation and lot records are maintained internally for traceability support
Works best alongside a low-fat diet
Wu, G., Fang, Y.-Z., Yang, S., et al., Glutathione metabolism and its implications for health, J
Neurology (Review)